Key result
In patients treated with digoxin fab antibodies, the FPIA-UF assay yielded a significantly lower mean area under the concentration-time curve than BDS or EMIT (86.1 vs 158.1 and 176.3 h.ng/ml; p<0.01).
Why the study?
Do BDS and EMIT assays provide reliable free serum digoxin concentrations compared to FPIA-UF in digoxin toxic patients treated with fab antibodies?
Population
n=8 digoxin toxic patients treated with digoxin fab antibodies
Comparison
Baxter Dade Stratus and Syva affinity column… vs Abbott TDx fluorescence polarization immunoassay…
Design
Case_series
Follow-up
up to 204 hours post therapy
Authors
Loading...
BDS/EMIT may overestimate free digoxin AUC post-fab; this case report leaves open the optimal assay for toxicity monitoring.
Observational (n=8)
Do BDS and EMIT assays provide reliable free serum digoxin concentrations compared to FPIA-UF in digoxin toxic patients treated with fab antibodies?
p-value: p=<0.01
FPIA-UF is the preferred assay for determining free serum digoxin concentrations during digoxin fab antibody therapy due to significant bias in BDS and EMIT assays.
Ujhelyi et al. (1992) conducted an observational in Digoxin toxicity (n=8). Baxter Dade Stratus (BDS) and Syva EMIT assays vs. Abbott TDx FPIA-UF reference assay was evaluated on Area under the serum digoxin concentration-time curve (p=<0.01). In patients treated with digoxin fab antibodies, the FPIA-UF assay yielded a significantly lower mean area under the concentration-time curve than BDS or EMIT (86.1 vs 158.1 and 176.3 h.ng/ml; p<0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: